Similar articles

• Type-specific monoclonal antibody enhances the local phagocytic response to group B streptococcal infection.

  Shigeoka AO, Weber ME, Pincus SH, Pritchard DG, Egan ML, Hill HR. Shigeoka AO, et al. J Infect Dis. 1986 Jun;153(6):1170-3. doi: 10.1093/infdis/153.6.1170. J Infect Dis. 1986. PMID: 3517190 No abstract available.
• Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci.

  Hill HR, Gonzales LA, Knappe WA, Fischer GW, Kelsey DK, Raff HV. Hill HR, et al. J Infect Dis. 1991 Apr;163(4):792-8. doi: 10.1093/infdis/163.4.792. J Infect Dis. 1991. PMID: 2010632
• Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci.

  Shigeoka AO, Jensen CL, Pincus SH, Hill HR. Shigeoka AO, et al. J Infect Dis. 1984 Jul;150(1):63-70. doi: 10.1093/infdis/150.1.63. J Infect Dis. 1984. PMID: 6379061
• Immunoglobulin therapy of neonatal group B streptococcal infections: an overview.

  Fischer GW. Fischer GW. Pediatr Infect Dis J. 1988 May;7(5 Suppl):S13-6. Pediatr Infect Dis J. 1988. PMID: 3041355 Review.
• Bacterial carbohydrates in neonatal sepsis: targets for immunotherapy.

  Raff HV. Raff HV. Springer Semin Immunopathol. 1993;15(2-3):173-81. doi: 10.1007/BF00201099. Springer Semin Immunopathol. 1993. PMID: 8256196 Review. No abstract available.